PMID- 25673892
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150212
LR  - 20221010
IS  - 0018-5787 (Print)
IS  - 1945-1253 (Electronic)
IS  - 0018-5787 (Linking)
VI  - 49
IP  - 11
DP  - 2014 Dec
TI  - Economic Impact of Converting from Pen and 10-mL Vial to 3-mL Vial for Insulin 
      Delivery in a Hospital Setting.
PG  - 1033-8
AB  - PURPOSE: To compare the impact on acquisition cost and purchased volume of rapid- 
      and short-acting insulins following conversion from 3-mL disposable pens and 
      10-mL vials to 3-mL vials for individual patient supply (IPS) in a hospital 
      setting. METHODS: On February 1, 2010, St. Joseph's Hospital and Medical Center 
      of Dignity Health in Phoenix, Arizona, converted from pens to 3-mL vials for IPS 
      subcutaneous (SC) injection and from 10-mL short-acting insulin vials to 3-mL 
      vials for intravenous (IV) preparation. Pharmacy purchasing data were analyzed 
      over 6-month periods before and after conversion (March 1 through August 31, 
      2009, and March 1 through August 31, 2010). RESULTS: Before conversion, 
      acquisition costs were $27,866 for 5,335 mL of rapid-acting insulins and $53,336 
      for 26,310 mL of short-acting insulins. After conversion, insulin acquisition 
      costs were $24,211 for 5,850 mL of rapid-acting insulins (13.1% decrease in 
      costs, 9.7% rise in volume), with cost reduction attributable to the lower cost 
      of 3-mL vials. Acquisition costs were $17,395 for 14,700 mL of short-acting 
      insulins after conversion (67.4% decrease in costs, 44.1% reduction in volume), 
      with cost reduction attributable to lower cost of 3-mL vials versus pens for IPS 
      SC injections and 10-mL vials for IV preparation. The reduction in purchased 
      volumes of short-acting insulins may be partly due to decreased insulin use in IV 
      preparation. CONCLUSION: Conversion from pens and 10-mL vials to 3-mL vials for 
      rapid-and short-acting insulins resulted in reduced acquisition costs and 
      decreased use of short-acting insulin in IV preparations.
FAU - Elizabeth, Eby
AU  - Elizabeth E
AD  - Eli Lilly and Company, Indianapolis , Indiana.
FAU - Smolen, Lee
AU  - Smolen L
AD  - Medical Decision Modeling Inc. , Indianapolis, Indiana.
FAU - Pitts, Amber
AU  - Pitts A
AD  - Medical Decision Modeling Inc. , Indianapolis, Indiana.
FAU - Krueger, Linda A
AU  - Krueger LA
AD  - Eli Lilly and Company, Indianapolis , Indiana.
FAU - Grimm, Doneen
AU  - Grimm D
AD  - St. Joseph's Hospital and Medical Center of Dignity Health , Phoenix, Arizona .
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pharm
JT  - Hospital pharmacy
JID - 0043175
PMC - PMC4319803
OTO - NOTNLM
OT  - 3-mL vial
OT  - conversion
OT  - cost
OT  - insulin
OT  - pens
EDAT- 2015/02/13 06:00
MHDA- 2015/02/13 06:01
PMCR- 2015/12/01
CRDT- 2015/02/13 06:00
PHST- 2015/02/13 06:00 [entrez]
PHST- 2015/02/13 06:00 [pubmed]
PHST- 2015/02/13 06:01 [medline]
PHST- 2015/12/01 00:00 [pmc-release]
AID - 10.1310/hpj4911-1033 [doi]
PST - ppublish
SO  - Hosp Pharm. 2014 Dec;49(11):1033-8. doi: 10.1310/hpj4911-1033.